Cancer Health Drugs: Lorbrena (lorlatinib) - Cancer Health
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non–Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib - Clinical Lung Cancer
Lorlatinib Reduces CNS Progression in ALK-Positive NSCLC | MedPage Today
Lorlatinib (Pfizer Inc) | Bioz | Ratings For Life-Science Research
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study | SpringerLink
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants | SpringerLink
A user's guide to lorlatinib - ScienceDirect
Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma | NEJM
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer | Nature Communications
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM
Assessment report
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study - The Lancet Oncology
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease - Journal of Thoracic Oncology
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer | Nature Cancer
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial - The Lancet Oncology
Lorviqua Full Prescribing Information, Dosage & Side Effects | MIMS Malaysia
Practical management of major Lorlatinib side effects — ALK POSITIVE
A user's guide to lorlatinib - ScienceDirect
Lorlatinib Tablets
Median plasma concentration versus time profiles for lorlatinib (a) and... | Download Scientific Diagram
Lorlatinib (Pfizer Inc) | Bioz | Ratings For Life-Science Research
Lorlatinib - LiverTox - NCBI Bookshelf
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study | SpringerLink
Pharmaceuticals | Free Full-Text | Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis | HTML
a Plasma lorlatinib and b metabolite (M8) concentration-time profiles... | Download Scientific Diagram
